When was seragy founded?

seragy was founded in 2022 and raised its 1st funding round 4 years after it was founded.

Where is seragy located?

seragy is headquartered in Hannover, Germany.

Is seragy a funded company?

seragy is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Oct 14, 2026.

When was the latest funding round of seragy?

seragy's latest funding was a $***** Series B round on Oct 14, 2026, with participation from 2 investors.

Where does seragy rank among its competitors?

seragy ranks 75th amongst 59 active competitors, of which 14 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was seragy, which secured $13.4M in Oct, 2026.

Who are the top competitors of seragy?

seragy's top competitors include Octave Bioscience, Amprion and PeopleBio R&D. Among them, seragy secured the most recent funding round in October, 2026.

seragy - 2026 Company Profile, Funding & Competitors

seragy is a series B company based in Hannover (Germany), founded in 2022. It operates as a Developer of analytical platforms to detect misfolded protein disease seeds. seragy has raised $13.4M in funding. The company has 59 active competitors, including 14 funded and 6 that have exited. Its top competitors include companies like Octave Bioscience, Amprion and PeopleBio R&D.

Company Details

Developer of analytical platforms to detect misfolded protein disease seeds. The technology amplifies traces of misfolded proteins within biological samples to generate molecular fingerprints. These fingerprints facilitate the identification of disease subtypes and support the creation of quantitative biomarkers for drug development. The methodology focuses on protein aggregation research to characterize proteopathies.

Key Metrics

Founded Year

2022

Location

Hannover, Germany

Stage

Series B

Total Funding

$13.4M in 1 round

Latest Funding Round

Series B, Oct 14, 2026, $*****

Investors

Commerzbank & 2 more

Ranked

75^th among 75 competitors

Similar Companies

Octave Bioscience & 73 more

View seragy's full profile

seragy has raised a total funding of $13.4M over 1 round. Its latest funding round was a Series B round on Oct 14, 2026 for $*****. 2 investors participated in its latest round. seragy has 3 institutional investors.

Here is the list of recent funding rounds of seragy:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 14, 2026	5794061	Series B	1480293	9164371	6561825	8499317

Access funding benchmarks and valuations. Sign up today!

View details of seragy's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of seragy include Octave Bioscience, Amprion and PeopleBio R&D. Here is the list of Top 10 competitors of seragy, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Octave Bioscience 2014, Menlo Park (United States), Series C	Provider of AI-based molecular diagnostic tools for neurodegenrative diseases	$124M	Novartis, BVF & 17 others	66/100
2nd	Amprion 2006, Houston (United States), Series B	Revolutionizing neurodegenerative disease diagnosis with advanced α-synuclein detection technology	$11.8M	Formationve, Lilly & 3 others	56/100
3rd	PeopleBio R&D 2002, Seongnam-si (South Korea), Public	Immunoassays for early detection of neuro-degenerative diseases	-	DT&Investment, GNTech Venture Capital & 12 others	48/100
4th	LikeMinds 2008, Boston (United States), Series A	Provider of dopamine transporter imaging agent for diagnosis of neurodegenerative diseases	$6.37M	-	38/100
5th	Nanostics 2017, Edmonton (Canada), Seed	Developer of diagnostic tests to detect cancers, cardiovascular and neurodegenerative diseases	-	indyRIOT	37/100
6th	Cytox 2007, Oxford (United Kingdom), Series B	Developer for prognostic tests for assessing the risk of dementia	$12.1M	Maven Capital Partners, Northwest Fund & 22 others	36/100
7th	Durin Life Sciences 2010, United States, Acquired	Early disease detection blood tests for Alzheimer's and Parkinson's	$5.5M	-	34/100
8th	Alseres Pharmaceuticals 1972, Auburndale (United States), Public	Therapeutic and diagnostic products for disorders in the central nervous system (CNS)	$4M	Ingalls and Snyder	34/100
9th	Durin Technologies 2010, Camden (United States), Series B	Developer of the diagnostic test for neurodegenerative diseases	$8.05M	Breakthrough Diagnostics	32/100
10th	Mag4health 2021, Grenoble (France), Unfunded	Developer of quantum based technology for non invasive brain functional disorder detection	-	-	32/100
75th	seragy 2022, Hannover (Germany), Series B	Developer of analytical platforms to detect misfolded protein disease seeds	$13.4M	Commerzbank, Ermoeglicher & 1 others	28/100